Laurus Labs Limited (BOM:540222)
India flag India · Delayed Price · Currency is INR
595.55
+2.65 (0.45%)
At close: May 13, 2025
36.16%
Market Cap 320.99B
Revenue (ttm) 55.54B
Net Income (ttm) 3.58B
Shares Out n/a
EPS (ttm) 6.64
PE Ratio 89.58
Forward PE 53.91
Dividend 1.20 (0.20%)
Ex-Dividend Date May 9, 2025
Volume 206,673
Average Volume 107,336
Open 594.00
Previous Close 592.90
Day's Range 593.00 - 607.20
52-Week Range 386.85 - 660.90
Beta n/a
RSI 45.54
Earnings Date Apr 25, 2025

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational ser... [Read more]

Industry Medicinal Chemicals and Botanical Products
Founded 2005
Employees 6,007
Stock Exchange Bombay Stock Exchange
Ticker Symbol 540222
Full Company Profile

Financial Performance

In 2024, Laurus Labs's revenue was 55.54 billion, an increase of 10.18% compared to the previous year's 50.41 billion. Earnings were 3.58 billion, an increase of 123.18%.

Financial Statements

News

There is no news available yet.